First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

PURPOSE: CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC). We assessed the association of efficacy with programmed death ligand 1 (PD-L1) expres...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Clin Oncol
Autores principales: Ready, Neal, Hellmann, Matthew D., Awad, Mark M., Otterson, Gregory A., Gutierrez, Martin, Gainor, Justin F., Borghaei, Hossein, Jolivet, Jacques, Horn, Leora, Mates, Mihaela, Brahmer, Julie, Rabinowitz, Ian, Reddy, Pavan S., Chesney, Jason, Orcutt, James, Spigel, David R., Reck, Martin, O’Byrne, Kenneth John, Paz-Ares, Luis, Hu, Wenhua, Zerba, Kim, Li, Xuemei, Lestini, Brian, Geese, William J., Szustakowski, Joseph D., Green, George, Chang, Han, Ramalingam, Suresh S.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Clinical Oncology 2019
Materias:
ORIGINAL REPORTS
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494267/
https://ncbi.nlm.nih.gov/pubmed/30785829
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.01042
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares